Navigation Links
OXIS International, Inc. Announces Publication of Positive Results of Ergothioneine Safety Study in the Journal 'TOXICOLOGY'
Date:8/19/2010

BEVERLY HILLS, Calif., Aug. 19 /PRNewswire-FirstCall/ -- OXIS INTERNATIONAL, INC. (OTC Bulletin Board: OXIS, Paris: OXI) is proud to announce that an Oxis sponsored safety study of ergothioneine was published online on July 30, 2010 by the prestigious peer reviewed journal, TOXICOLOGY.  The study, utilizing the well known "Ames Test" was conducted by researchers from the American Institute of Biomedical Research (Puyallup, WA) and Toxi-Coop Zrt. (Budapest, Hungary) and clearly demonstrated the absence of any mutagenic effect associated with ergothioneine in the study model. The study will be in print shortly in a special nutraceutical issue of TOXICOLOGY.

In a letter to Dr. Alexander Schauss, lead researcher on the study, Dr. Kendall B. Wallace, PhD,  Managing Editor of TOXICOLOGY, stated, "Your accepted paper is considered to be a significant contribution to the field of toxicology and we appreciate the opportunity to publish it in this journal."

"This study represents the continuing commitment by Oxis to further solidifying the already extensive foundation of safety and efficacy studies supporting the unique nutraceutical compound, ergothioneine," stated Bernie Landes, President of Oxis. "This is an important milestone in our plans to introduce a wide range of proprietary and uniquely beneficial ergothioneine based products, including dietary supplements, functional foods and beverages and personal care products," Landes added.

About OXIS International, Inc.

OXIS International, Inc. develops technologies and products to provide superior solutions to health challenges associated with oxidative stress/inflammation associated with damage from free radical and reactive oxygen species (ROS). The company holds the rights to several therapeutic classes of compounds in the area of oxidative stress, and has focused commercialization programs that include SOD (superoxide dismutase), MPO (myeloperoxidase), GPx (glutathione peroxidase), as well as a highly potent antioxidant, Ergothioneine, that may be sold over-the-counter (OTC) as a dietary supplement.

Forward-Looking Statement

This press release contains forward-looking statements that involve numerous risks and uncertainties. Actual results, performance or achievements could differ materially from those anticipated in such forward-looking statements as a result of certain factors, including those set forth in the Company's filings with the Securities and Exchange Commission.

www.oxis.com


'/>"/>
SOURCE OXIS International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Arno Therapeutics, Inc. Completes $18 Million Financing and Reverse Merger with Laurier International, Inc.
2. Medizone International, Inc. (MZEI.PK): Trials of the AsepticSure Hospital Sterilization System Have Begun
3. Chindex International, Inc. to Report Second Quarter Fiscal 2010 Financial Results
4. Chindex International, Inc. Reports Second Quarter and First Half Fiscal 2010 Financial Results
5. Natural Alternatives International, Inc. Announces Filing of Patent Infringement Lawsuit
6. DATATRAK International, Inc. Announces Year-End Backlog
7. New Database from ANSI, AAMI, ASTM International, and DIN Provides Centralized Source of Information for Medical Device Professionals
8. DAVISCO Foods International, Inc. and MEGGLE Group Announce a Joint Venture for the Production of Pharmaceutical Lactose.
9. Lexington International, LLC Receives 2009 U.S. Presidents E Award Recognizing its Export Achievements
10. International, Well-Known Scientific Experts Say That New GFT505 Data Unlikely to Have the Potential to Affect the Established Role of Generic Fenofibrate and Bezafibrate in Managing Atherogenic Dyslipidemia
11. International Growth Continues: Rhythmlink International, LLC Receives CE Marking & ISO 13485 Certification
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)...   Risperdal lawsuits involving gynecomastia (male breast growth) ... of the atypical antipsychotic medication continue to move forward ... Common Pleas, where the state,s Risperdal docket has been ... notice posted on the Court,s website , the ... 9, 2017 at 11:00 a.m. (In Re: Risperdal Litigation, ...
(Date:2/17/2017)... LOUIS , Feb. 17, 2017   FormFast ... has announced a new partnership with Engage , ... the United States . FormFast will serve as ... of Engage,s implementations with MEDITECH .  ... provides essential functionality to complement and enhance the electronic ...
(Date:2/17/2017)... , Feb. 17, 2017  BioDigital, Inc., ... the partnership of their 3D body mapping technology ... IT.  The new integration will be used to ... interactive model of the human body. BioDigital pilots ... clinicians time, while also increasing the precision of ...
Breaking Medicine Technology:
(Date:2/18/2017)... (PRWEB) , ... February 17, 2017 , ... ... leading source of disruptive innovation in the industry, according to the recent NEJM ... are based on surveys of the NEJM Catalyst Insights Council, a qualified group ...
(Date:2/18/2017)... ... February 17, 2017 , ... ... , Beverly Hills plastic surgeon Dr. Glenn Vallecillos experiments SculpSure, ... Vallecillos says, "Traditionally, plastic surgery has been centered around that idea that to ...
(Date:2/18/2017)... (PRWEB) , ... February 18, 2017 , ... ... presets. Use Pixel Film Studios ’ ProParagraph Fashion Volume 2 for ... so many other applications. Users can pick and choose from hand-crafted trend-setting ...
(Date:2/17/2017)... ... ... Smiles by Seese is a comprehensive family dental practice located ... practice as a skilled and highly credentialed dentist who is qualified to perform a ... all ages with excellence in general, restorative, and cosmetic dentistry . Their services ...
(Date:2/17/2017)... ... February 17, 2017 , ... ... sustainable systems change designed to further positively impact the health and wellness of ... has long considered it our duty to seriously consider releasing our assets beyond ...
Breaking Medicine News(10 mins):